伏诺拉生联合阿莫西林、克拉霉素的三联方案根除幽门螺杆菌的效果评价研究  

Efficacy Evaluation on Vorosuvastatin Combined with Amoxicillin and Clarithromycin in the Eradication of Helicobacter Pylori

作　　者：刘宏明[1] 王敏[2] 孟雅洁 王建[1] LIU Hongming;WANG Min;MENG Yajie;WANG Jian(Dept.of Pharmacy,Nanchuan People’s Hospital Affiliated to Chongqing Medical University,Chongqing 408400,China;Dept.of Gastroenterology,Nanchuan People’s Hospital Affiliated to Chongqing Medical University,Chongqing 408400,China)

机构地区：[1]重庆医科大学附属南川医院药剂科,重庆408400 [2]重庆医科大学附属南川医院消化内科,重庆408400

出　　处：《中国医院用药评价与分析》2025年第2期157-160,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：重庆市科卫联合医学科研项目(No.2022QNXM038)。

摘　　要：目的:评价伏诺拉生联合阿莫西林、克拉霉素的三联方案根除幽门螺杆菌(Hp)的效果及安全性,为临床决策提供依据。方法:将2022年1月至2023年6月在该院消化内科判定为首次需要根除Hp的患者180例采用随机数字表分为观察1组、观察2组和对照组,每组60例。观察1组和观察2组患者均采用伏诺拉生、阿莫西林及克拉霉素三联方案治疗7 d,仅阿莫西林服用剂量不同;对照组患者采用艾司奥美拉唑、阿莫西林及克拉霉素根除方案治疗7 d。三组患者抗Hp疗程结束1个月后复查14C尿素呼气试验,分析三组患者的Hp根除率、临床症状改善及不良反应发生情况。结果:180例患者中,失访6例,其中观察1组失访1例,观察2组失访2例,对照组失访3例。观察1组、观察2组和对照组患者的Hp根除率分别为91.53%(54/59)、91.38%(53/58)和87.72%(50/57),观察1组、观察2组与对照组比较,差异有统计学意义(P<0.05)。三组治疗方案均能有效改善患者腹胀、反酸、口腔异味、胃痛和胃胀症状,观察1组、观察2组与对照组比较,差异有统计学意义(P<0.05)。观察1组、观察2组和对照组患者的不良反应发生率分别为6.78%(4/59)、8.62%(5/58)和10.53%(6/57),观察1组、观察2组与对照组比较,差异有统计学意义(P<0.05)。结论:伏诺拉生联合阿莫西林、克拉霉素的三联方案在根除Hp和症状改善方面优于基于艾司奥美拉唑的三联方案,治疗安全性相当。OBJECTIVE:To evaluate the efficacy and safety of vorosuvastatin combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori(Hp),so as to provide evidence for clinical decision-making.METHODS:A total of 180 patients diagnosed as requiring Hp eradication for the first time in the Dastroenterology department of the hospital from Jan.2022 to Jun.2023 were divided into the observation group 1,observation group 2 and control group by the random number table method,with 60 cases in each group.The observation group 1 and observation group 2 received a 7-day triple regimen of vorosuvastatin,amoxicillin and clarithromycin,with the only difference being the dosage of amoxicillin taken.The control group received a 7-day eradication regimen of esomeprazole,amoxicillin and clarithromycin.^(14)C urea breath test was reexamined 1 month after the end of anti-HP treatment.The eradication rate of Hp,improvement of clinical symptoms and occurrence of adverse drug reactions in three groups were analyzed.RESULTS:Among 180 patients,6 cases were lost to follow-up,including 1 case in observation group 1,2 cases in observation group 2,and 3 cases in the control group.The eradication rates of Hp in observation group 1,observation group 2,and control group was respectively 91.53%(54/59),91.38%(53/58),and 87.72%(50/57),there was a statistically significant difference(P<0.05)between observation group 1,observation group 2,and the control group.observation group 1 and observation group 2 were higher than the control group,but there was no statistically significant difference among three groups(P>0.05).The three treatment regimens could effectively improve the symptoms of abdominal distension,acid reflux,oral odor,stomach pain,and bloating in patients,observation group 1 and observation group 2 were better than the control group,but there was no statistically significant difference among three groups(P>0.05).there was a statistically significant difference(P<0.05)between observation group 1,observation group 2,and the

关 键 词：伏诺拉生 三联方案 幽门螺杆菌 根除率 

分 类 号：R975[医药卫生—药品] R978.1[医药卫生—药学]